# Nanobiotix Cash Runway Meets Clinical Progress

> Nanobiotix's cash runway until 2029 supports JNJ-1900 trials amid clinical progress.
- Title: Nanobiotix Cash Runway Meets Clinical Progress | Shortify
- Summary: Nanobiotix's cash runway until 2029 supports JNJ-1900 trials amid clinical progress. Nanobiotix's EUR 110.9 million cash runway funds operations through 2029…
- Keywords: nanobiotix, jnj-1900, nanoray-312, clinical-stage, cash runway, oncology, Cash, Runway, Meets, Clinical, Progress, Alphastreet - Earnings Decoded. Market Intelligence Delivered
- Source: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/nanobiotix-s-a-nbtx-earnings-review-clinical-progress-meets-a-cash-runway-test
- Author: Newsdesk
- Published: 2026-09-29T15:16:09+00:00
- Read time: 1 min
- Topics: nanobiotix, jnj-1900, nanoray-312, clinical-stage, cash runway, oncology
## Quarterly Results
Nanobiotix reported EUR 5.6 million revenue for first half 2026.

> Nanobiotix reported revenue of EUR 5.6 million for the first half of 2026
## Revenue Drop
Revenue fell from EUR 26.4 million in first half 2025 to EUR 5.6 million in first half 2026.

> revenue of EUR 5.6 million for the first half of 2026, compared with EUR 26.4 million for the first half of 2025
## Net Loss
Net loss was EUR 34.3 million for first half 2026 versus EUR 5.4 million in first half 2025.

> net loss of EUR 34.3 million for the first half of 2026, compared with a net loss of EUR 5.4 million for the first half of 2025
## Cash Position
Cash and equivalents stood at EUR 110.9 million as of June 30, 2026.

> cash and cash equivalents of EUR 110.9 million at June 30, 2026
## Runway Timeline
Management expects cash to fund operations through 2029.

> this cash position was expected to fund operations into 2029
## Clinical Focus
JNJ-1900 progress in head and neck cancer trials remains key for value.

> the company continued to focus on advancing JNJ-1900 and supporting the Johnson & Johnson collaboration
## Key takeaway

Nanobiotix's EUR 110.9 million cash runway funds operations through 2029 while advancing JNJ-1900 in head and neck cancer trials.